Other cancer types such as colorectal, ovarian and lung cancers also occasionally (less than 10% of cases) exhibit activating BRAF mutations that in turn stimulate SCF-βTrcp2/HOS ligase activity that ubiquitinates several tumour suppressors (often cell cycle inhibitors or cytokines) and promotes tumour progression [34]. This evidence concerns the gene KITLG and neoplasm.